After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...